Company / Cost of Revenue
Emergent BioSolutions Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$326.2M
FY2025
5-year range
$326.2M / $748.1M
FY2021-FY2025
Trend
-52.1%
vs FY2024
Sector context
#29 of 85
Health Care
What the data says
At $326M, Emergent BioSolutions Inc.'s cost of revenue ranks #57 of 85 in the Health Care sector. Cost of Revenue has fluctuated over the past 10 years, ranging from $126M in FY2018 to $748M in FY2021.
Based on SEC 10-K filings.
$326M in FY2025 with a 5-year CAGR of -9.0%.
Improved from $705M to $326M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -22.2%
- 5-Year CAGR
- -9.0%
- 10-Year CAGR
- -
Sector benchmark
#57 of 85 in Health CareTop 66% of 85This company $326.2M Sector average $2.0B
▼
-83.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.0%, indicating a declining trend.
- In FY2025, cost of revenue decreased 52.1% year-over-year.
- Ranks #29 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $326.2M | -52.1% |
| FY2024 | $681.3M | -3.4% |
| FY2023 | $705.4M | +1.8% |
| FY2022 | $693.1M | -7.4% |
| FY2021 | $748.1M | +42.8% |
| FY2020 | $524.0M | +20.9% |
| FY2019 | $433.5M | +243.2% |
| FY2018 | $126.3M | -32.7% |
| FY2017 | $187.7M | +48.6% |
| FY2016 | $126.3M | +17.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026